Want to join the conversation?
Foster City, California-based drug maker $GILD said that the U.S. Food and Drug Administration has approved Odefsey for the treatment of HIV-1 infection. Odefsey is $GILD's second TAF-based regimen to receive FDA approval, and represents the smallest pill of any single tablet regimen for the treatment of HIV.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.